In a Dec. 23 statement, Astellas Pharma US said it has notified customers of one lot of Prograf and another lot of Astagraf XL. Prograf is prescribed to prevent rejections of kidney, heart, liver or lung transplants, while Astagraf XL is for kidney transplants.
Ingesting empty capsules could result in transplant rejection, which can be fatal for patients with life-sustaining organ transplants such as a heart. No adverse events have been reported, Astellas said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
